The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Open accessAbstract
Efficacy of antiangiogenic immunotherapy is associated with intratumoral formation of high endothelial venules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the multiple preclinical studies, angiogenesis inhibitor enhanced the efficacy of α-PD-1/PD-L1 in murine tumor models [106–108].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [108]
In the citing paper
“These findings suggest that the superior therapeutic response achieved with VEGFA-targeting agents plus PD-L1 inhibitors may involve an unsuspected vascular component”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Allen et al., 2017
In the citing paper
“over time, tumours again become hypoxic and escape from this combined treatment approach via upregulation of PD-L1 on tumour cells and stromal cells of the TME, including ECs and immune cells98.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [98]
In the citing paper
“The combination of anti-VEGFR2 and anti-PD-L1 antibodies, however, did not improve survival in a glioblastoma model98.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [98]
In the citing paper
“upregulation of PD-L1 has been demonstrated on both ECs and tumour cells following treatment with anti-VEGFR2 therapy98.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [98]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“INTRODUCTION Sustained angiogenesis and immunosuppression are hallmarks of cancer (1).”
BackgroundSelf-citationPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“In addition, sufficient T cell infiltration in human tumors appeared to be a rate-limiting step for responses to PD-L1 blockade (33, 53).”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“In line with this concept, antiangiogenic therapy normalizes tumor blood vessels, albeit transiently, resulting in better blood and oxygen flow and possibly alsomore efficient T cell extravasation from the blood into the tumor (56, 57).”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“Retrospective clinical studies have shown correlations between tumor PD-L1 expression and response to PD-1/ PD-L1 checkpoint blockade therapy (51, 52).”
BackgroundInnate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · cited 1×
“This is based on the observation that cell constituents of tumors can express various surface molecules (such as PD-L1) that engage receptors (such as PD-1) on the surfaces of activated T cells, causing T cell anergy or exhaustion (6, 7).”
BackgroundCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Self-citationImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Recent preclinical studies have also shown that antiVEGF therapy can improve anti-PD-L1 (programmed deathligand 1) treatment, specifically when it generates intratumoral high endothelial venules (HEVs) that facilitate enhanced cytotoxic T lymphocyte (CTL) infiltration and tumor cell destruction (Allen et al., 2017).”
BackgroundEnhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Metadata
- Authors
- Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., & Bergers, G.
- Affiliations
- VIB-KU Leuven Center for Cancer Biology (BE)
- University of California, San Francisco (US)
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Allen, Elizabeth
- Jabouille, Arnaud
- Bergers, Gabriele
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-04-12
- Volume
- 9
- Issue
- 385
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5554432
- OpenAlex
- W2605792367
- Cited by
- 820
- References
- 71
- Citations by year
- 2026: 78 · 2025: 92 · 2024: 87 · 2023: 103 · 2022: 113 · 2021: 109 · 2020: 89 · 2019: 70 · 2018: 55 · 2017: 24
- FWCI
- 28.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Funders
- NIH (U54CA163155, R01CA188404, RO1CA20153)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- anti-angiogenic therapy, PD-L1 blockade, high endothelial venules, VEGFR-2 inhibition, PD-L1, antitumor immunity, interferon-gamma, PD-1/PD-L1 immune checkpoint, cytotoxic T lymphocytes, lymphocyte infiltration, glioblastoma, pancreatic neuroendocrine tumors, breast cancer, combination immunotherapy, tumor vasculature
- MeSH terms
- Animals, Breast Neoplasms, Female, Interferon-gamma, Mice, Inbred C57BL, Neoplasm Recurrence, Local, Pancreatic Neoplasms, T-Lymphocytes, Cytotoxic, Signal Transduction, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. https://app.cochat.ai/papers/10.1126/scitranslmed.aak9679
- The paper
- Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., & Bergers, G. (2017). Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aak9679
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.